# Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer

> **NCT00193453** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 69 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Docetaxel
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT00193453
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2009-02
- **Final completion:** 2009-12
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2012-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00193453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00193453, "Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00193453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*